SOURCE: Herborium Group, Inc.

Herborium Group, Inc.

January 20, 2011 09:30 ET

Herborium Group, Inc. Joined by the Former President of Pfizer China

SADDLE BROOK, NJ--(Marketwire - January 20, 2011) - Herborium Group, Inc. (PINKSHEETS: HBRM) www.herborium.com, a Botanical Therapeutics™ company, announced today that it added Mr. Laurence Woo to the company Board of Directors.

Mr. Woo brings to Herborium over 30 years of experience in the pharmaceutical industry in Asia and Greater China (PRC, Hong Kong and Taiwan) in sales, marketing and planning, and over 16 years of senior line management experience in this region. Mr. Woo, who in addition to his BS in Science from Hong Kong University is also an alumnus of Advanced Management Courses at Harvard and Dartmouth Universities, has served as General Manager for Bristol-Myers-Squibb, Korea, General Manager Southeast Asia (1988-1994); President and General Manager Pfizer, China (1994-1997); and President and Managing Director of Wyeth Pharmaceuticals PRC, Taiwan and Hong-Kong (1997-2004).

"We are delighted to welcome Mr. Woo into the Herborium family. He is bringing to us his most valuable expertise in developing Chinese market opportunities and to foster our pursuit of most valuable botanical therapeutic candidates," commented Dr. Agnes P. Olszewski, Herborium Group's President and CEO. "We expect Mr. Woo to play a vital role in our efforts to execute our 'Road-to-Market' Strategy calling for revenue projections of $7.5 Million, with a goal to capture 1% of the Global Natural and Alternative Treatments Market," Olszewski concluded.

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, develops, licenses and markets proprietary, botanical based medicines to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. For more information, please visit www.herborium.com.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.

Contact Information

  • Investor & Media Relations:
    Steve Haag
    (832) 577-2380